Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
about
New advances in DPYD genotype and risk of severe toxicity under capecitabine.Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.Pharmacogenetics and breast cancer management: current status and perspectives.Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.Therapeutic drug monitoring of 5-fluorouracil.Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.'Toxgnostics': an unmet need in cancer medicineCost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
P2860
Q33648195-0363DA0C-DE22-4BF7-B5B4-589E88C80C76Q35743233-F15C48D3-F057-4A93-8A9C-EEACBAF5E595Q36410237-82604EE6-5F87-4187-A809-94F8BE7516AFQ36618144-C3F2230C-6271-4E51-BB12-6BD1D4042250Q37706746-C6CC4AAD-633D-4FFD-B06E-F0BF7B4EF1E1Q38358816-629E3B20-121F-44F2-9F24-3FD576241534Q38565029-7BB39860-276F-45FA-8F7D-25C0741EC798Q38842633-039A8FD2-80A2-460A-B5D7-D51C01BD7863Q39857880-F204C9F6-118D-4021-B2E4-A073BBF7DBA0Q40811026-10EA46E4-3FE9-4787-9533-5D53C132995BQ47135784-C48B2225-DF82-4CAA-89F7-4428BE7F21D1Q47768032-D3C0BAD9-822A-4683-89D7-4C6CC612077DQ47796934-5A657075-742A-49D9-B3CC-3E8C44E50D6CQ50089496-B373B2C1-19B5-4DC6-A16F-1D2D3D175EBEQ50577018-D3F3F76F-490D-4818-ADA4-4D757C9A6D45Q53513271-D07C937B-D20B-41B4-AAB2-A9E203ECFBCAQ53558675-CCCC4BC9-E00F-4944-B3B9-49A791634780Q55155089-04218FCC-7099-4799-9309-885D15C6857AQ56675475-082A48FA-563D-4EEC-9CE6-EF0C28DF361BQ57054536-77F17BD3-65D5-4E49-BC8B-F3AD11B11347
P2860
Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Evaluation of predictive tests ...... dine dehydrogenase deficiency.
@en
type
label
Evaluation of predictive tests ...... dine dehydrogenase deficiency.
@en
prefLabel
Evaluation of predictive tests ...... dine dehydrogenase deficiency.
@en
P2093
P2860
P356
P1476
Evaluation of predictive tests ...... idine dehydrogenase deficiency
@en
P2093
A B P van Kuilenburg
H Gelderblom
J G Maring
M C van Staveren
P2860
P2888
P304
P356
10.1038/TPJ.2013.25
P577
2013-07-16T00:00:00Z
P5875
P6179
1043156166